ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Fluorescence lifetime imaging ophthalmoscopy (FLIO) of patients with neovascular age-related macular degeneration before and after treatment with intravitreal ranibizumab.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNeovascular age-related macular degeneration (AMD) is a leading cause of severe vision loss worldwide. Although intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections improve outcomes, frequent treatments are burdensome and responses vary. This study investigates changes in macular fluorescence lifetime before and after anti-VEGF therapy using fluorescence lifetime imaging ophthalmoscopy (FLIO), and explores FLIO parameters as potential biomarkers for treatment response.
methodsTwenty patients with neovascular AMD underwent FLIO imaging (excitation: 473 nm; emission: short spectral channel [SSC]: 498-560 nm; long spectral channel [LSC]: 560-720 nm) and macular OCT before and 4-6 weeks after ranibizumab injection. Fluorescence lifetime components (mean τ
resultsChanges in FLIO parameters post-treatment varied individually without a consistent trend. However, statistically significant correlations were found between changes in BCVA (∆logMAR) and changes in τ
conclusionFLIO parameters correlated with visual acuity changes, while retinal thickness did not. This suggests that FLIO may capture treatment-induced alterations beyond structural changes, potentially reflecting metabolic processes. FLIO may therefore serve as a valuable adjunct tool for monitoring anti-VEGF therapy response in neovascular AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.